<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074186</url>
  </required_header>
  <id_info>
    <org_study_id>D001-PRT21-026</org_study_id>
    <nct_id>NCT05074186</nct_id>
  </id_info>
  <brief_title>Assessing the Safety and Effectiveness of a Neurological Thrombectomy Medical Device for Acute Ischemic Stroke</brief_title>
  <official_title>Assessing the Safety and Effectiveness of a Neurological Thrombectomy Medical Device for Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University at Buffalo Jacobs Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Jacobs Institute is participating in a Sponsor Investigator study designed to collect&#xD;
      prospective clinical evidence to evaluate the use of a neurological thrombectomy device for&#xD;
      clot retrieval in acute ischemic patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The neurological thrombectomy device is an investigational device&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate technical efficacy outcomes with radiographical measurements</measure>
    <time_frame>Day 1</time_frame>
    <description>The occurrence of all serious adverse device effects up to 90-days post-procedure Modified Thrombolysis in Cerebral Infarction (mTICI) score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>outcomes with radiographical measurements</measure>
    <time_frame>day 1</time_frame>
    <description>The occurrence of all serious adverse device effects up to 90-days post-procedure Modified Thrombolysis in Cerebral Infarction (mTICI) score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate technical efficacy outcomes with radiographical measurements</measure>
    <time_frame>Day 3</time_frame>
    <description>The occurrence of all serious adverse device effects up to 90-days post-procedure Modified Thrombolysis in Cerebral Infarction (mTICI) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate technical efficacy outcomes with radiographical measurements</measure>
    <time_frame>90 days</time_frame>
    <description>The occurrence of all serious adverse device effects up to 90-days post-procedure Modified Thrombolysis in Cerebral Infarction (mTICI) score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>neurological thrombectomy device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Revascularization device is an investigational device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>neurological thrombectomy device is an investigational device.</intervention_name>
    <description>Revascularization device is an investigational device.</description>
    <arm_group_label>neurological thrombectomy device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        at least 18 years of age at time of consent Has baseline National Institutes of Health&#xD;
        Stroke Scale (NIHSS) â‰¥ 8; Able to be treated within 8 hours of stroke symptom onset or Last&#xD;
        Known Normal (LKN);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cannot provide consent or legally authorized representative not available to provide&#xD;
        consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Gay, CCRP</last_name>
    <phone>7164404231</phone>
    <email>jgay@ubns.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>kaledia Health/Buffalo General Medical Center/GVI</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Gay</last_name>
      <phone>716-440-4231</phone>
      <email>jgay@ubns.com</email>
    </contact>
    <investigator>
      <last_name>Adnan Siddiqui, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Adnan H. Siddiqui</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

